Novartis AG NOVN

Investing.com -- Deutsche Bank on Thursday named its top European stock picks for the next 12 months, adding six new names and dropping six from its third-quarter list.

AI-driven discovery, streamlined approvals and partnerships are accelerating drug repurposing, creating opportunities in oncology, rare, neurodegenerative and infectious diseases.Dublin, Sept. 30, 2026 (GLOBE NEWSWIRE) -- "Drug Repurposing Market - Global Strategic Business Report" has been added to ResearchAndMarkets.com's offering. The global drug repurposing market was valued at US$29.4 billion in 2024 and is projected to reach US$37.3 billion by 2030, expanding at a compound annual growth ra

The global CAR T-cell therapy market is projected to grow from USD 7.24 billion in 2026 to USD 13.78 billion by 2031, registering a 13.7% CAGR. Growth is driven by rising cancer prevalence, technological advances, expanding clinical trials, and increased investment, while high costs and adverse effects remain barriers. Yescarta led the product market in 2025, hospitals were the largest end-user segment, and Asia Pacific is forecast to record the fastest growth through 2031.Dublin, Sept. 30, 2026

CAS, a division of the American Chemical Society, today announced a collaboration with Novartis Biomedical Research focused on enhancing reaction data accessibility and supporting AI-enabled research. The initiative will leverage CAS unique scientific data curation expertise and science-smart technology to give Novartis researchers integrated, searchable access to proprietary experimental reaction data alongside more than 160 million+ scientist-curated reactions from the authoritative CAS Conten

Arthex Biotech, a clinical-stage biotechnology company advancing RNA-based therapeutics for neuromuscular disorders, today announced the appointment of Glenn Sblendorio, M.B.A., as Chairman of its Board of Directors. Mr. Sblendorio is a seasoned biotechnology executive and board member with more than three decades of experience leading corporate strategy, finance, business development and capital markets initiatives. Most recently, he was Chief Executive Officer of IVERIC bio, Inc. (acquired by

On September 18, Novartis AG (NYSE:NVS) announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending marketing authorization for Cosentyx (secukinumab) to treat polymyalgia rheumatica (PMR) in adults who respond inadequately to steroids or relapse during tapering. Following this recommendation, the European Commission is expected to issue a […]

On September 1, 2026, the Wall Street Journal first reported that Novartis AG (NYSE:NVS) paused eight clinical trials of its experimental CAR-T cell therapy rap-cel in autoimmune and neurological conditions, including lupus, rheumatoid arthritis, and multiple sclerosis. It happened after three patients died from immune effector cell-associated hemophagocytic syndrome, a rare and severe immune reaction. […]

Big pharma is still paying up, but more often for delivery and discovery engines than for a single late-stage asset.

On September 10, 2026, Reuters reported that Artisan Partners, among Novartis AG (NYSE:NVS)’ 20 largest shareholders, publicly called for a shake-up of the Swiss drugmaker’s board to improve oversight of its acquisitions, after Novartis shares suffered an 11% one-day drop this week. It wiped out nearly $30 billion in market value and erased all of […]

Novartis (SWX:NOVN) has signed an exclusive global license agreement with BoomRay Pharmaceuticals for a preclinical radioligand therapy asset. The deal gives Novartis worldwide rights to develop and commercialise the BoomRay program as part of its radiopharmaceutical pipeline. The agreement adds another early stage oncology candidate to Novartis' radioligand therapy efforts, expanding its presence in targeted cancer treatments. This new BoomRay radioligand license sits within a wider pattern...

Novartis gained approval of a drug in IgAN with the same target as Roche’s sefaxersen in 2026.

Novartis AG’s (NYSE:NVS) Phase 3 Lp(a)HORIZON setback carries implications beyond the Swiss drugmaker. Pelacarsen significantly lowered lipoprotein(a), or Lp(a), but failed to produce a statistically significant reduction in major cardiovascular events, according to the information provided. READ ALSO: Can a Tagrisso Combination Strengthen AstraZeneca’s Path to $80 Billion? That disconnect matters for companies developing other […]

While remigromig is non-inferior to Lucentis in terms of efficacy, questions around its tolerability remain.

VRTX is expanding beyond its CF stronghold with a promising kidney disease pipeline led by povetacicept and inaxaplin.

The global pharmaceutical drug delivery market is projected to grow from USD 2.15 trillion in 2026 to USD 2.92 trillion by 2031, registering a 6.3% CAGR. Growth is driven by rising chronic disease prevalence, biologics, biosimilars, advanced therapies, self-administration and connected drug-device technologies. Injectable drug delivery led the market in 2025, while hospitals were the largest facility segment. North America dominated due to advanced healthcare infrastructure, strong R&D and wides

Sefaxersen reduced proteinuria at 37 weeks, while kidney function and failure outcomes require longer observation.

The results position Roche to bring a new kind of medicine to market for IgA nephropathy, a disease that’s drawn considerable attention of late from drugmakers.

IONS posts positive phase III results for two partnered drugs, with ulefnersen meeting its ALS endpoint and sefaxersen cutting proteinuria.